The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, jointly sponsored by the U.S. National Heart, Lung, and Blood Institute and the World Health Organization, was released in 2000. Although there have been several discussions regarding the diagnosis of chronic obstructive pulmonary disease (COPD), the GOLD guidelines recommended a forced expiratory volume at one second per forced vital capacity (FEV1/FVC) < 70% as follows: "For the diagnosis and assessment of COPD, spirometry is the gold standard as it is the most reproducible, standardized, and objective way of measuring airflow limitation. The diagnosis is confirmed by an objective measure of airflow limitation, preferably spirometry. An FEV1/FVC <70% to defining an early sign of airflow limitation is a pragmatic one in view of the fact that universally applicable references values for FEV1 and FVC are not available." Several epidemiologic and clinical studies have reported that the major risk factors for COPD were smoking and age. However, the standard criterion of the GOLD guidelines was used in a few studies in Europe and the United States.

In the present study, the standard criterion on the GOLD guidelines for the diagnosis of COPD is used, and the effects of age and smoking on COPD in Japan are evaluated.
Subjects
Subjects in this study were participants aged 25-74 years subject-
ed to health check-ups including spirometry at the Toyota Community Medical Center in Japan from April 2001 through March 2002. Out of 11,839 participants, 149 with asthma and 240 with tuberculosis were excluded because of the difficulty involved in diagnosing COPD by spirometry; this left 11,460 participants for analysis. Table 1 shows the number of subjects grouped by sex and age at 5-year intervals. The number of subjects thus grouped ranged from 31 to 1,611.

COPD diagnosis
Spirometry (DISCOM 21 or MICROSPIRO HI-501; CHEST MI., Ins., Tokyo, Japan) was performed by experienced technicians. The largest value was chosen from among single and multiple spirometry examination results. FVC and FEV1 were measured, and FEV1/FVC was calculated. According to the standard criteria using the GOLD guidelines, subjects were diagnosed as COPD for FEV1/FVC less than 70%.

Table 1. Number of subjects.

| Age (years) | Males | Females |
|------------|-------|---------|
| Total      | 7,574 | 3,886   |
| 25-29      | 48    | 31      |
| 30-34      | 236   | 70      |
| 35-39      | 783   | 300     |
| 40-44      | 1,173 | 555     |
| 45-49      | 1,342 | 808     |
| 50-54      | 1,611 | 882     |
| 55-59      | 1,373 | 790     |
| 60-64      | 628   | 300     |
| 65-69      | 254   | 101     |
| 70-74      | 126   | 49      |

Table 2. Characteristics of subjects by sex and smoking status.

|              | Males | Females |
|--------------|-------|---------|
|              | n     | cases of COPD (%) | n     | cases of COPD (%) |
|Total         | 7,574 | 188(2.4) | 3,886 | 25(0.6) |
|Never smokers | 1,890 | 19(1.0)  | 3,565 | 20(0.6) |
|Former smokers| 2,120 | 51(2.4)  | 118  | 0(0.0)  |
|Current smokers| 3,564 | 188(3.3) | 203  | 5(2.5)  |
|Brinkman Index | <400  | 900(2.2) | 161  | 2(1.2)  |
|              | 400-799 | 1,685 | 43(2.6) | 34 | 2(5.9)  |
|              | 800+   | 979   | 55(5.6) | 8 | 1(12.5) |

*: Chronic obstructive pulmonary disease.
□: Brinkman Index: number of cigarettes per day □ total number of years smoking.

Smoking status
A self-administered questionnaire on smoking status was used, including the number of cigarettes per day and the years since starting smoking. Subjects were classified by smoking status into three groups: non-smokers, former smokers and current smokers. Current smokers were classified by the Brinkman Index (BI) into three groups: BI <400, 400-799, and 800+. The BI was determined as the number of cigarettes per day multiplied by the years since starting smoking.16

Data analysis
Data from the subjects mentioned above were available for sex, age, smoking status, BI, FVC and FEV1, but did not include any personal identifiers, such as name and address. To evaluate the association between age and COPD, logistic regression analyses with or without COPD as a dependent variable and age as an independent variable were conducted among both male and female non-smokers.

To evaluate the association between smoking and COPD adjusted for age, the ratio of the observed number of COPD cases to their expected number (O/E) was calculated for each group, i.e., former smokers, current smokers and current smokers of BI <400, 400-799, and 800+ among males and females. The expected number of COPD cases in each group was estimated as the total of the expected proportions of COPD among their subjects, which were calculated by the estimated logistic regression equation for non-smokers and their ages.

The statistical significance of O/E was tested under the assumption that the observed number of COPD cases assumed a Poisson distribution. The 95% confidence interval (CI) of O/E was estimated by an approximate method. If there were no observed COPD cases, an exact method was used. The trend in O/E over BI categories was tested by the Mantel test. The scores of BI categories of BI <400, 400-799, and 800+ were given as 200, 600 and 1,000, respectively. These analyses were performed using an SPSS® 10.0J software package (SPSS Japan Inc.).
COPD and smoking status

Table 2 shows the number of COPD cases by smoking status. The number of current smokers was 3,564 (47.1%) in males and 203 (5.7%) in females, while the number of COPD cases was 188 (2.4%) in males and 25 (0.6%) in females. The proportion of COPD cases among current smokers was higher than that among non-smokers. The number of COPD cases in each BI group was more than 20 in males and less than 2 in females. The proportion of COPD cases increased with BI.

**Association between COPD and age**

The curves of estimated proportions of COPD cases by age among non-smokers and those observed in the age groups are illustrated in Figure 1 for males and in Figure 2 for females. The proportion of COPD cases by age was estimated as $1/[1 + \exp (7.595 - 0.058 \times \text{age})]$ in males and $1/[1 + \exp (7.482 - 0.044 \times \text{age})]$ in females. Those estimates were comparatively consistent with the observed proportions in age groups except for the 70-74 year female age group. The estimated proportion significantly increased with age in males ($p = 0.02$), but not in females ($p = 0.11$). The increase per 10 years of age in the estimated proportion was 1.79-fold in males and 1.55-fold in females.

**Association between COPD and smoking status**

Figure 3 shows the ratio of the observed number of COPD cases to the number expected for non-smokers with the same age distribution (O/E) by smoking status, excluding O/E in female current smokers with 800+ BI because of their small numbers. Among Kojima S, et al.

Table 2 shows the number of COPD cases by smoking status. The number of current smokers was 3,564 (47.1%) in males and 203 (5.7%) in females, while the number of COPD cases was 188 (2.4%) in males and 25 (0.6%) in females. The proportion of COPD cases among current smokers was higher than that among non-smokers. The number of COPD cases in each BI group was more than 20 in males and less than 2 in females. The proportion of COPD cases increased with BI.

**Association between COPD and age**

The curves of estimated proportions of COPD cases by age among non-smokers and those observed in the age groups are illustrated in Figure 1 for males and in Figure 2 for females. The proportion of COPD cases by age was estimated as $1/[1 + \exp (7.595 - 0.058 \times \text{age})]$ in males and $1/[1 + \exp (7.482 - 0.044 \times \text{age})]$ in females. Those estimates were comparatively consistent with the observed proportions in age groups except for the 70-74 year female age group. The estimated proportion significantly increased with age in males ($p = 0.02$), but not in females ($p = 0.11$). The increase per 10 years of age in the estimated proportion was 1.79-fold in males and 1.55-fold in females.

**Association between COPD and smoking status**

Figure 3 shows the ratio of the observed number of COPD cases to the number expected for non-smokers with the same age distribution (O/E) by smoking status, excluding O/E in female current smokers with 800+ BI because of their small numbers. Among Kojima S, et al.

Table 2 shows the number of COPD cases by smoking status. The number of current smokers was 3,564 (47.1%) in males and 203 (5.7%) in females, while the number of COPD cases was 188 (2.4%) in males and 25 (0.6%) in females. The proportion of COPD cases among current smokers was higher than that among non-smokers. The number of COPD cases in each BI group was more than 20 in males and less than 2 in females. The proportion of COPD cases increased with BI.

**Association between COPD and age**

The curves of estimated proportions of COPD cases by age among non-smokers and those observed in the age groups are illustrated in Figure 1 for males and in Figure 2 for females. The proportion of COPD cases by age was estimated as $1/[1 + \exp (7.595 - 0.058 \times \text{age})]$ in males and $1/[1 + \exp (7.482 - 0.044 \times \text{age})]$ in females. Those estimates were comparatively consistent with the observed proportions in age groups except for the 70-74 year female age group. The estimated proportion significantly increased with age in males ($p = 0.02$), but not in females ($p = 0.11$). The increase per 10 years of age in the estimated proportion was 1.79-fold in males and 1.55-fold in females.

**Association between COPD and smoking status**

Figure 3 shows the ratio of the observed number of COPD cases to the number expected for non-smokers with the same age distribution (O/E) by smoking status, excluding O/E in female current smokers with 800+ BI because of their small numbers. Among Kojima S, et al.
EFFECTS OF SMOKING AND AGE ON COPD

Many epidemiologic studies have reported that FEV₁/FVC decreased with age, whereas there have been only a few studies on the association between COPD and age. The South Korea Study indicated that the proportion of cases with FEV₁/FVC < 75% among males and females 45 years old or older was 4.3 times higher than among younger subjects. Our study confirmed that the proportion of COPD cases increased with age in male non-smokers in Japan under the standard diagnostic criteria for COPD. We failed to detect any significant association between COPD and age in female non-smokers. This might be due to the fact that our subjects were younger than 75 years of age, did not include many older females, or that collecting accurate information about smoking was difficult in females, or that the increase in COPD cases among female non-smokers was lower than among male non-smokers.

Our study showed that COPD was significantly associated with smoking status in both males and females in Japan. The South Korea Study indicated that the age-adjusted odds ratio of cases with FEV₁/FVC < 75% in smokers with BI <400 compared with non-smokers was 3.2. A Greek study reported that the age-adjusted odds ratio of COPD in smokers with BI ≥300 compared with smokers with BI <300 was 1.5 in males and 4.7 in females under the standard diagnostic criteria for COPD, but it did not report comparative results between smokers and non-smokers. In our study, O/E for current smokers with BI <400, 400-799, 800+ were 3.10, 2.78, and 4.76, respectively, suggesting a dose-response relationship between COPD and smoking for males in Japan. These findings indicated that smoking constituted a strong risk factor for COPD. O/E for former smokers in males was 2.06. Smoking years after former smokers quit and quantities per day would be given more consideration.

There are several limitations and problems in our study. Although the GOLD diagnostic criterion of COPD is a recognized standard, it is not perfect. It might be important for diagnosing COPD to examine measures other than FEV₁/FVC such as some definitions for airway obstruction and symptoms or histories related to COPD. Because those with diseases such as asthma and tuberculosis would not be suitable subjects for the criteria due to the difficulty in accurately measuring FVC and FEV₁ by spirometry, then were excluded from our analysis. Although spirometry was performed by experienced technicians in our study, the FVC and FEV₁ would inevitably include measurement variations. Moreover, our subjects were participants in a health check-up at a community medical center rather than being randomly selected from a community population, and they did not include many female smokers because of the relatively low smoking rate among Japanese females. Our study design was cross-sectional, whereas a large-scale longitudinal study would be important for more accurately evaluating the effects of age and smoking on COPD.

The authors wish to thank Mr. Yukio Kawamoto at the Toyota Community Medical Center for his valuable collaboration.

REFERENCES

1. Siafakas NM, Vermeire P, Pride NB, Paolotti P, Gibson J, Howard P, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-420.
2. American Thoracic Society. Evaluation of impairment/disability secondary to respiratory disorders. Am Rev Respir Dis 1986; 133: 1205-9.
3. The committee for COPD (chronic obstructive pulmonary disease) guidelines 2nd ed, the Japanese Respiratory Society eds. COPD guidelines for diagnosis and treatments, 2nd ed. Medical Review. Tokyo, 2004 (in Japanese).
4. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76.
5. Takemura H, Hida W, Sasaki T, Miura N, Sen T. The Relation between prevalence of chronic obstructive pulmonary disease and smoking habit by occupation of subjects on human Dry Dock. HEP 2003; 30: 581-6.
6. Takemura H, Hida W, Sasaki T, Miura N, Sen T. Prevalence of chronic obstructive pulmonary disease and smoking habit in subjects on human Dry Dock. HEP 2003; 30: 217-21.
7. Omori H, Morimoto Y. Effects of smoking habits on pulmonary function: Cross-sectional and longitudinal studies in male subjects on medical check-up. Nihon Kokyuki Gakkai Zasshi 2004; 42: 306-12. (in Japanese)
8. Shin C, In KH, Shim JJ, Yoo SH, Kang KH, Hong M, et al. Prevalence and correlates of airway obstruction in a community-based sample of adults. Chest 2003; 123: 1924-31.
9. Krzyzanowski M, Jedrzychowski W, Wysocki M. Factors associated with the change in ventilatory function and the development of chronic obstructive pulmonary disease in a 13-year follow-up of the Cracow Study: Risk of chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 134: 1011-9.
10. Lange P, Groth S, Nyboe J, Appleyard M, Mortensen J, Jensen G, et al. Chronic obstructive lung disease in Copenhagen: cross-sectional epidemiological aspects. J Intern Med 1989; 226: 25-32.
11. Chen Y, Breithaupt K, Muhajarine N. Occurrence of chronic obstructive pulmonary disease among Canadians and sex-related risk factors. J Clin Epidemiol 2000; 53: 755-61.
12. Tzanakis N, Anagnostopoulou U, Filaditaki V, Christaki P, Siafaras N. Prevalence of COPD in Greece. Chest 2004; 125: 892-900.
13. von Hertzen L, Reunanen A, Impivaara O. Airway obstruction in relation to symptoms in chronic respiratory disease: a nationally representative population study. Respir Med 2000; 94: 356-63.
14. Xu X, Weiss ST, Rijcken B, Schouten JP. Smoking, change in smoking habits, and rate of decline in FEV1: New insight into gender differences. Eur Respir J 1994; 7: 1056-61.
15. Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: What is the true burden of disease? Chest 2003; 123: 1684-92.
16. Brinkman GL, Coates EO Jr. The effect of bronchitis, smoking and occupation on ventilation. Ann Rev Respir Dis 1963; 87: 684-93.
17. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659-64.
18. Miller A, Thornton JC, Warshaw R, Bernstein J, Selikoff IJ, Teirstein AS. Mean and instantaneous expiratory flows, FVC and FEV1: prediction equations from a probability sample of Michigan, a large industrial state. Bull Eur Physiopathol Respir 1986; 22: 589-97.
19. Paoletti P, Pistelli G, Fazzi P, Viegi G, Pede FD, Giuliano G, et al. Reference values for vital capacity and flow-volume curves from a general population study. Bull Eur Physiopathol Respir 1986; 22: 451-9.
20. Viegi G, Pedreschi M, Pistelli F, Pede FD, Baldacci S, Carrozzi L, et al. Prevalence of airway obstruction in a general population. European Respiratory Society vs. American Thoracic Society definition. Chest 2000; 117: 339s-345s.